The particulars: 97.9% · ecnoglutide · WWB.
I would like to define my thresholds before I have a result, for obvious reasons.
I want a plan with explicit stopping rules, not just steps.
What is the minimum version of this that is still defensible?
Concretely, purity is a method-dependent figure, and that is not a limitation of the measurement, it is a property of what the measurement actually answers.
Retention time is sequence-specific and method-specific, so comparing your result to a supplier value using a different method is meaningless without method documentation.
In practice, temperature affects the dynamics of molecular conformation, and if a peptide has proline residues that interconvert on the chromatographic timescale, the peak will split or shoulder at low temperature and collapse at high temperature.
The Arrhenius relationship for peptide degradation is the basis of accelerated stability testing and also governs how quickly methods drift with temperature.
The caveat is that purity without identity is only half an answer — a high purity does not mean the peak is actually what you think it is.
If you are ranking vendors, specify a method and have all samples tested at the same place.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsMore usefully, understanding purity requires separating the chemistry from the method from the reporting convention, and the three are not independent.
Sample solvent strength affects peak shape — if you inject in strong solvent on a gradient starting in weak solvent, the solvent peak can distort your main peak or create a false shoulder.
Specifically, tailing factor measures peak shape, and a badly tailing peak spreads into the region where small impurities live, forcing tangent-skim integration that assigns tail area to the main peak.
Proline conformer interconversion kinetics are well-characterised and the half-life is of the same order as the chromatographic peak width at room temperature.
Compare purity within a single laboratory on the same method, never across laboratories.
The underlying point is that the honest answer is that the achievable range of plausible purity figures for a given vial is wider than most people expect.
Mobile phase additive choice affects ionisation and peak shape — TFA gives sharp peaks but suppresses mass spectrometry signal, formic acid gives worse peaks but preserves signal.
The relevant detail is that the fraction of your main peak that is actually your target versus isomers, fragments or related sequences is invisible without complementary identity testing.
Inter-laboratory studies on identical peptide material routinely find half-a-per-cent to a full-per-cent spreads in reported purity on the same sample.
I would be careful about over-reading a single measurement — treat it as a data point, not as ground truth.
The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.
edited 2 Jan 2025 by Dr_Jonas_Halvorsen — fixed an arithmetic slip in the third paragraph
Area percentage is not mass percentage, and conflating the two is the most common misreading of a purity figure.
Column pore size affects mass transfer — a 100 Angstrom packing on a 5 kDa peptide restricts diffusion, broadening the peak and potentially hiding small impurities in the shoulders.
Worth noting that method standardisation is poor in the research-grade space compared to pharmaceutical work, so identical-looking methods can produce different results.
If you are ranking vendors, specify a method and have all samples tested at the same place.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.